Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now
The model's full reasoning — Q1 2018 call → NOWe need to determine if management describes a second, distinct way of making money that emerged from existing operations, assets, customers, or capabilities, and is already generating real paying business today while being deliberately grown. The transcript discusses the acquisition of Biosynthetic Technologies. That is an acquisition, not something that emerged from existing operations. However, the acquisition is integrated with existing capabilities: they have an esters plant in Missouri that can manufacture some of the products, and they have distribution channels. But the acquisition itself is a separate company, not a second avenue that grew out of what they already do. The question says "NO if the second business came chiefly from acquiring an unrelated company rather than emerging from the company's own operations." Here, Biosynthetic Technologies is an acquisition, but it is related to their specialty products. However, the origin is an acquisition, not something that grew out of their own operations. They are leveraging existing plant and distribution, but the technology and product line came from the acquisition. So that likely doesn't count. What about the ERP system? That is a cost-saving initiative, not a revenue stream. What about the self-help initiatives? Those are improvements to existing operations, not a second revenue avenue. What about the branded products division? That is part of their existing specialty products business, not a separate stream. What about the fuels segment and specialty segment? Those are two segments, but they are both core businesses. The question says "NO if the company is a conglomerate or multi-segment business simply reporting its usual several segments." So that doesn't count. What about the Midland WTI crude optimization? That is just sourcing cheaper crude, not a new revenue stream. What about the RINs? That is a regulatory benefit, not a distinct business. What about the Biosynthetic Technologies? They are excited about it, but it is an acquisition. They plan to commercialize it using their existing plant. But is it already generating paying business? The transcript says "We presently anticipate that we can achieve this key milestone while incurring very small capital costs" - that is future. They talk about "industrial proof of concept" and "commercialization" - it sounds like it's not yet paying.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.